Logo image
IRO Home Research units Researcher Profiles
Sign in
Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer
Journal article   Peer reviewed

Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer

M Hillenbrand, M Bastian, M Steiner, C Zingler, M Müller, J M Wolff, H Seiter and P Schuff-Werner
Anticancer research, Vol.20(6D), pp.4995-4996
11/2000
PMID: 11326656

View Online

Abstract

Prostate-specific antigen (PSA) is the single most important tumor marker in early detection and monitoring of prostate cancer (CaP). However, routine analysis of serum PSA concentrations does not allow differentiation between CaP and prostatic diseases. The aim of the present study was to evaluate the usefulness of the serum-to-urinary PSA ratio in a clinical setting.
Prostatic Hyperplasia - urine Prognosis Prostatic Hyperplasia - diagnosis Prostatic Neoplasms - urine Prostate-Specific Antigen - urine Humans Prostatic Neoplasms - blood Male Prostatic Hyperplasia - blood Aged Prostatic Neoplasms - diagnosis Prostate-Specific Antigen - blood

Details

Metrics

Logo image